Aurora A overexpression in breast cancer patients induces taxane resistance and results in worse prognosis.
J BUON
; 20(6): 1414-9, 2015.
Article
em En
| MEDLINE
| ID: mdl-26854435
ABSTRACT
PURPOSE:
The aim of this study was to determine the expression level of Aurora A in human breast cancer tissues and to test whether there is a relationship between its expression levels and clinicopathological parameters including response to taxanes, tumor grade, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, and overall survival (OS).METHODS:
We retrospectively analyzed paraffin-embedded tissue sections from 49 metastatic breast cancer patients whose clinical outcomes had been tracked after taxane treatment. The expression status of Aurora A was defined by immunohistochemistry (IHC) using the anti-Aurora A antibody.RESULTS:
Aurora A was overexpressed in 73% of the examined specimens. There was significant correlation between high Aurora A expression and decreased taxane sensitivity (p=0.02). There was no association between the clinicopathological parameters including histologic grade, ER positivity and triple negative molecular subtype and the level of Aurora A expression. However, HER2 positive tumors showed significantly higher Aurora A expression compared with HER2 negative tumors (p=0.02). Kaplan-Meier survival analysis failed to show a significant correlation between expression levels of Aurora A and OS although patients with low Aurora A levels had a marginally longer survival compared to patients with high levels.CONCLUSION:
Our data suggest that Aurora A may be a promising predictive and prognostic marker in patients with breast cancer.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Hidrocarbonetos Aromáticos com Pontes
/
Taxoides
/
Aurora Quinase A
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article